This is a phase III European multicenter, open label, prospective study to assess the
diagnostic accuracy of the use of SonoVue contrast agent to guide prostate biopsies in
comparison with the current practice of ultrasound guided systematic biopsy. The trial will
involve 15-20 European Centers.